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These include siRNA and microRNA used to degrade mRNA tran-
scripts and suppress protein translation, and antisense oligonucleo-
tides used to manipulate splicing.
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Pharmacogenetics and other factors in 
individualization of oral anti-vitamine k 
anti-coagulants
P. Beaune*
Université Paris-Descartes, Paris, France
Summary: The use of vitamin K antagonists (VKA) is challenging 
because of their narrow therapeutic index and a large interindividual 
variability. Pauci data were available regarding the relative contribu-
tion of pharmacogenetic and nongenetic factors to VKA response 
in specific populations (elderly, children, resistant patients). In 2 
cohorts of elderly patients receiving warfarin (n = 300) or fluin-
dione (n = 156), genetic factors were the main determinants of the 
maintenance dose, explaining ~20% of the variability versus ~10% 
for nongenetic factors. The variables significantly associated with the 
maintenance dose were VKORC1/CYP2C9/CYP4F2/EPHX1 and age 
for warfarin, and VKORC1/ABCB/CYP4F2, weight, and amiodar-
one intake for fluindione by multivariate analysis. During warfarin 
initiation, VKORC1 genotype had a strong predictive value for war-
farin sensitivity. When building prediction models of the warfarin 
dose, VKORC1/CYP2C9 were the best predictors before initiation, 
whereas their contribution was negligible once INR value was avail-
able after starting warfarin using a standardized regimen.
In the children cohort (n = 120), height and VKORC1/CYP2C9 
were the main determinants of warfarin dose requirement, explaining 
70% of the variability accounting for 48% and 20%, respectively.
Among the 100 patients resistant referred to us for analysis, only 
30 patients were carriers of VKORC1 mutations for which in vitro 
functional characterization was performed. Our results suggest the 
involvement of other genetic factors in VKA resistance.
Pharmacogenetics will help the development of personalized med-
icine to improve safety and efficacy during VKA treatment. Whether 
genetic testing improves long-term anticoagulation control in patients 
receiving VKA and prone to instability remains to be determined.
Disclosure of Interest: None declared.
Public health genomics and Personalized 
healthcare
A. Brand*
Institute for Public Health Genomics (IPHG), Maastricht 
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Summary: Rapid scientific advances and tools in genomics such 
as in the light of epigenomics, microbiomics, and systems biology 
supported by new ICT solutions not only contribute to the under-
standing of disease mechanisms but also provide the option of new 
promising applications in human health management during the 
whole life-course. What was a little time ago a vision for a new era 
of public health, in which advances from the -omic sciences would 
be integrated into strategies aiming at benefiting population health, 
is now responding to the very pressing need for the development of 
effective personalized health care, going even beyond personalized 
medicine based on a systems medicine approach. Although the utility 
of most genetic tests and biomarkers is still not evidence based, the 
real take-home message stops here and is a different one. In the per-
sonalized medicine setting, the traditional assessment and evaluation 
tools just do not work anymore. Thus, we clearly face the need for 
a new paradigm moving from population health to personal health. 
The paradigm shift depends on the willingness to restructure poli-
cies, and there is a clear urgency to prepare health care systems and 
policy makers in time.
So far, all stakeholders, including policy makers and the pri-
vate sector, are struggling to translate the emerging knowledge 
into public health. Public Health Genomics (PHG) is the area of 
public health ensuring that scientific advances in genomics (“from 
cell...”) triggered by innovative technologies are timely, effectively, 
and responsibly translated into health policies and practice for the 
benefit of population health (“...to society”). The implementation of 
PHG requires increased concerted activities. The Institute for Public 
Health Genomics (IPHG) at Maastricht University aims to fulfill 
this task in all European Member States by hosting the European 
Centre for Public Health Genomics (ECPHG) and coordinating the 
Public Health Genomics European Network (PHGEN). Furthermore, 
it closely collaborates with the European Science Foundation (ESF 
Forward Look on Personalised Medicine), the European Alliance 
for Personalised Medicine (EAPM), and the European Flagship Pilot 
ITFoM on the future of medicine, being one of the most ambitious 
worldwide, large-scale, science-driven, research initiatives that aim 
to achieve the visionary goal of the “virtual human.”
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a systematic follow-uP of student-
Prescribers (track): theraPeutic 
knowledge, skills/comPetencies  
and attitude
D. Brinkman*
Clinical Pharmacology & Pharmacy, VU University Medical 
Center, Amsterdam, the Netherlands
Summary: One of the core objectives of medical curricula is to provide 
graduates with a sufficient level of therapeutic knowledge and skills. 
Over the last decade, a lot has changed when it comes to teaching 
medical students how to prescribe rationally. In the Netherlands, most 
medical curricula shifted from a so-called problem-based learning to 
a context-learning pharmacotherapy program. However, there is still 
no systematic approach available for assessing students’ therapeu-
tic knowledge and skills during such a context-learning curriculum. 
Research on this topic consists almost exclusively of descriptive and 
evaluative studies on different assessment methods. These studies show 
that the often-used single-shot assessments have their shortcomings 
and poorly meet the recent developments in medical education (con-
text-learning). What is needed is a systematic approach to assessment.
In this session, David Brinkman proposes a new systematic model 
(TRACK) for assessing students’ therapeutic knowledge, skills/com-
petencies, and attitude during a context-learning curriculum. This 
longitudinal model is based on a set of assessment principles that are 
interpreted from empirical evidence. He discusses a number of chal-
lenges and opportunities around the proposed model and presents 
preliminary findings of this new project. One of its prime virtues is 
that it enables therapeutic assessment toward an assessment design 
that is underpinned by empirically grounded theory and, moreover, 
carefully follows students until they are prescribers.
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Summary: Most of the novel targeted anticancer agents share clas-
sical characteristics that define drugs as candidates for blood con-
centration monitoring: long-term therapy; high interindividual but 
restricted intraindividual variability; significant drug–drug and drug–
food interactions; correlations between concentration and efficacy/
toxicity with rather narrow therapeutic index; reversibility of effects; 
and absence of early markers of response. Surprisingly though, thera-
peutic concentration monitoring has received little attention for these 
drugs despite reiterated suggestions from clinical pharmacologists. 
Several issues explain the lack of clinical research and development 
in this field: global tradition of empiricism regarding treatment 
monitoring, lack of formal conceptual framework, ethical difficul-
ties in the elaboration of controlled clinical trials, disregard from 
both drug manufacturers and public funders, limited encouragement 
from regulatory authorities, and practical hurdles making dosage 
adjustment based on concentration monitoring a difficult task for 
prescribers. However, new technologies are soon to help us overcome 
these obstacles, with the advent of miniaturized measurement devices 
able to quantify circulating drug concentrations at the point-of-care, 
to evaluate their plausibility given actual dosage and sampling time, 
to determine their appropriateness with reference to therapeutic tar-
gets, and to advise on suitable dosage adjustment. Such evolutions 
could bring conceptual changes into the clinical development of drugs 
such as anticancer agents, while increasing the therapeutic impact of 
population PK-PD studies and systematic reviews. Research efforts 
in that direction from the clinical pharmacology community will 
be essential for patients to receive the greatest benefits and the least 
harm from new anticancer treatments. The example of imatinib, the 
first commercialized tyrosine kinase inhibitor, will be outlined to 
illustrate a potential research agenda for the rational development 
of therapeutic concentration monitoring.
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advances in genomics of blood Pressure—
time for translation
M. Caulfield*
William Harvey Research Institute, London, United Kingdom
Summary: In 2025, there will be 1.56 billion people worldwide 
with hypertension. Although evidence-based interventions have 
transformed blood pressure control, public health data show there 
is still poor blood pressure control, and new therapies are still needed. 
Paradoxically, more sophisticated understanding of pathogenesis 
coincides with a decline in licensing of new medicines for hyperten-
sion. Using discoveries from genomics of blood pressure could be 
used to select and validate drug targets, combining expertise in this 
area with model organism phenotyping, experimental medicine, and 
pharmacology alongside medicinal chemistry may assist. To reduce 
the cost, we could utilize the untapped potential of the electronic 
health record for clinical trial delivery, and “real-world” evaluation 
of clinical effectiveness could reduce some of the risks and costs of 
clinical development, allowing a new generation of molecules to be 
generated in an affordable manner.
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electronic solutions to safer hosPital 
Prescribing
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Summary: Routine clinical care in hospitals has become more reliant 
on digital technologies over the last decade. There are now a wide 
variety of electronic solutions aimed at improving patient safety and 
optimizing the use of medicines. This focused session will describe 
technologies available at key stages in the prescribing process: the 
decision to prescribe, the prescription generation, and the ongoing 
monitoring of therapy.
To support the decision-making process, prescribing information 
is available in many different point-of-care digital solutions across 
various platforms such as online computerized guidelines and smart-
phone applications. However, there is often overwhelming informa-
tion available to prescribers. Clinical decision support (CDS) tools 
can help because they allow more relevant information, often specific 
for the patient, to be embedded in the clinical workflow. Better still is 
the use of electronic prescribing medication administration (EPMA) 
systems either as standalone systems or as part of a wider electronic 
patient record. Such systems may influence prescribing decisions; 
for example, by promoting efficacious and cost-effective therapy. 
Other steps in the medicines use process can also be targeted by 
novel technologies such as automated dispensing systems and posi-
tive patient identification through barcode medication administra-
tion systems. Electronic medication administration records enable 
the precise monitoring of medication use on an individual patient 
surveillance level through to providing data for hospital-wide medi-
cation management strategies.
Individually, all of these have been shown to effect safe prescrib-
ing. The advantage of combining these technological advances—
which are already available in a limited number of integrated 
systems—cannot be underestimated and will become increasingly 
important to support tomorrow’s prescribers in providing optimal 
patient care.
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how to govern a self-Powered Patient: 
Privacy and bioPower
S. Coll*
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Summary: A range of new technologies is about to enable patients to 
produce a steady flow of information about their bodies: for example, 
heartbeat, blood pressure, sugar level, calories spent, temperature, 
sleep pattern. They are seen as useful to improve the quality of life 
and the accuracy of treatment for many patients, especially those with 
chronic diseases. This is probably the case when data are collected 
and analyzed by professionals. But since patients (or persons not 
suffering from any disease) will also be to monitor their own data 
without immediate supervision, there is a risk of misuse and get-
ting lost, that can lead to false or dangerous “homemade” medicine. 
Also, privacy of patients may be in danger. This is not only about 
preventing unauthorized persons from accessing these sets of very 
sensitive data, but probably to protect patients against themselves. 
Indeed, as some of them already post their genetic pattern on social 
networks, disclosing one’s own body’s parameter can potentially 
become a common practice. That would be extremely profitable for 
drug companies to sell their products, for example, or for insurance 
companies looking to filter good risks from bad ones. The lesson to 
be learned is that one should not consider that the data are available 
for any purpose just because the person decided to make his or her 
own data public, something that nobody will be ever able to forbid. 
Unfortunately, current data protection policies still consider data 
made public as… public. In fact, even a perfect protection of privacy 
could not address the problems of a complex relationship between 
information and power. To shed light on this subtle relationship, I will 
use the Michel Foucault’s concept of “biopower.” It will reveal that 
the project of developing techniques to build self-powered patients 
